ABX-IL8

Phase 2Small molecule

AAbgenix

ABX-IL8 is one of 32 small molecule programs targeting Chronic Bronchitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic BronchitisActive, not recruiting

Chronic BronchitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Chronic Bronchitis

#DrugCompanyPhaseTrials

Ketek

Sanofi

Approved

3 2

Daliresp

AstraZeneca

Approved

2 3

Kalydeco

Vertex Pharmaceuticals

Approved

1 4

Cipro

Theo-Dur

Levaquin

4 7

Avelox

Bayer

Phase 3

4 8

Serevent

GGlaxo Dba Glaxosmithkline

Approved

—9

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—10

Amoxicillin-Clavulanic Acid

Teva

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Bronchitis1 trial

A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD

Completed·AAbgenix·Phase 2·NCT00035828·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABX-IL8. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABX-IL8 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABX-IL8. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abgenix company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAbgenix

ABX-IL8

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Bronchitis1 trial

References

Drug Info

Quick Facts

Related News